Expert opinion on drug safety

Keyphrases

Publications

2023

Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety (2023)
Jianan Bao, Ling Zhou, Mengying Xu, Jingjing Ma
The impact of pharmacist intervention on the intravenous-to-oral switch therapy of proton pump inhibitors in cardiovascular surgery. Expert opinion on drug safety (2023)
António Cabral Lopes, Fatima Roque, Olga M Lourenço, Maria Teresa Herdeiro, Manuel Morgado
Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database. Expert opinion on drug safety (2023)
Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Phyllis I Spuls, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Michael T Nurmohamed, Bart J F van den Bemt, Martijn Bastiaan Adriaan van Doorn, Naomi T Jessurun
Sex differences in adverse drug reactions from adalimumab and etanercept in patients with inflammatory rheumatic diseases. Expert opinion on drug safety (2023)
Andrew Yeich, Ahmed Elhatw, Zaynab Ashoor, Kristen Park, Timothy Craig
Safety of medications for hereditary angioedema during pregnancy and lactation. Expert opinion on drug safety (2023)
Fangyuan Tian, Zhaoyan Chen, Bin Wu
Development and validation of a nomogram to predict the risk of potentially inappropriate medication use in older lung cancer outpatients with multimorbidity. Expert opinion on drug safety (2023)
Siyuan Gao, Yu Li, Zhichao He, Jianhong Zhu, Dan Liang, Shan Yang, Jiayao Mo, Kakei Lam, Xiaoxia Yu, Ming Huang, Junyan Wu
Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review. Expert opinion on drug safety (2023)
Qiongtong Fang, Fuqiang Huang, Jiabi Liang, Yishen Chen, Cheng Li, Meirong Zhang, Xinrong Wu, Wenji Luo
Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA Adverse Event Reporting System database. Expert opinion on drug safety (2023)
Lili Jiang, Yanyan Jia, Xiaoyu Wang, Zhe Wang, Xin Lv, Yaqin Jia, Yuyi Feng, Hang Yin, Mingrui Yan, Xiaoyu Fan, Yong Liu
Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis. Expert opinion on drug safety (2023)
António Cabral Lopes, Fatima Roque, Olga M Lourenço, Maria Teresa Herdeiro, Manuel Morgado
Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database. Expert opinion on drug safety (2023)
Yarden Yavne, Reut Amar Shamir, Michael Shapiro, Daniel Shepshelovich
Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database. Expert opinion on drug safety (2023)
Felicia Ceban, Mehala Subramaniapillai, Rodrigo B Mansur, Joshua D Rosenblat, Roger S McIntyre
Can COVID-19 have a Clinically Significant Effect on Drug Metabolism? Expert opinion on drug safety (2023)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Fangyuan Tian, Zhaoyan Chen, Bin Wu
Development and validation of a nomogram to predict the risk of potentially inappropriate medication use in older lung cancer outpatients with multimorbidity. Expert opinion on drug safety (2023)
Jianan Bao, Ling Zhou, Mengying Xu, Jingjing Ma
The impact of pharmacist intervention on the intravenous-to-oral switch therapy of proton pump inhibitors in cardiovascular surgery. Expert opinion on drug safety (2023)
Lili Jiang, Yanyan Jia, Xiaoyu Wang, Zhe Wang, Xin Lv, Yaqin Jia, Yuyi Feng, Hang Yin, Mingrui Yan, Xiaoyu Fan, Yong Liu
Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis. Expert opinion on drug safety (2023)
Guojun Dong, Naoko Adachi Kjærgaard, Saeed Shakibfar, Maurizio Sessa
Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies. Expert opinion on drug safety (2023)
Jin Zhao, Lihong Liu, Hao Li, Dan Sun, Yi Hu, Chen Zhang, Yuhui Zhang
Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials. Expert opinion on drug safety (2023)

volume 22, number 1, 2023

Andrew Yeich, Ahmed Elhatw, Zaynab Ashoor, Kristen Park, Timothy Craig
Safety of medications for hereditary angioedema during pregnancy and lactation. Expert opinion on drug safety 22 (1) (2023)
Karthik D Nath, Kitsada Wudhikarn, Ana Alarcon Tomas, Miguel-Angel Perales
Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Expert opinion on drug safety 22 (1) (2023)
Guojun Dong, Naoko Adachi Kjærgaard, Saeed Shakibfar, Maurizio Sessa
Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies. Expert opinion on drug safety 22 (1) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety 22 (1) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety 22 (1) (2023)
Karthik D Nath, Kitsada Wudhikarn, Ana Alarcon Tomas, Miguel-Angel Perales
Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Expert opinion on drug safety 22 (1) (2023)
Felicia Ceban, Mehala Subramaniapillai, Joshua D Rosenblat, Rodrigo B Mansur, Roger S McIntyre
Can COVID-19 have a clinically significant effect on drug metabolism? Expert opinion on drug safety 22 (1) (2023)
Andrew Yeich, Ahmed Elhatw, Zaynab Ashoor, Kristen Park, Timothy Craig
Safety of medications for hereditary angioedema during pregnancy and lactation. Expert opinion on drug safety 22 (1) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety 22 (1) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety 22 (1) (2023)
Guojun Dong, Naoko Adachi Kjærgaard, Saeed Shakibfar, Maurizio Sessa
Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies. Expert opinion on drug safety 22 (1) (2023)
Felicia Ceban, Mehala Subramaniapillai, Joshua D Rosenblat, Rodrigo B Mansur, Roger S McIntyre
Can COVID-19 have a clinically significant effect on drug metabolism? Expert opinion on drug safety 22 (1) (2023)
Karthik D Nath, Kitsada Wudhikarn, Ana Alarcon Tomas, Miguel-Angel Perales
Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Expert opinion on drug safety 22 (1) (2023)
Marco Di Monaco, Carlotta Castiglioni, Francesca Bardesono
Letter to the editor: consideration on: 'What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?' by Reid I.R. Expert opinion on drug safety 22 (1) (2023)
Marco Di Monaco, Carlotta Castiglioni, Francesca Bardesono
Letter to the editor: consideration on: 'What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?' by Reid I.R. Expert opinion on drug safety 22 (1) (2023)

volume 22, number 2, 2023

Liana Michaud, Matthew Seplowe, Juliet Meir, Wilbert S Aronow
Safety and cardiometabolic efficacy of novel antidiabetic drugs. Expert opinion on drug safety 22 (2) (2023)
Vijay K Singh, Thomas M Seed
The safety and efficacy of interleukin 11 for radiation injury. Expert opinion on drug safety 22 (2) (2023)
Vijay K Singh, Thomas M Seed
The safety and efficacy of interleukin 11 for radiation injury. Expert opinion on drug safety 22 (2) (2023)
Shuohan Huang, Zihan Guo, Mengmeng Wang, Youjun She, Xuan Ye, Qing Zhai, Jiyong Liu, Qiong Du
Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system. Expert opinion on drug safety 22 (2) (2023)
Shuohan Huang, Zihan Guo, Mengmeng Wang, Youjun She, Xuan Ye, Qing Zhai, Jiyong Liu, Qiong Du
Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system. Expert opinion on drug safety 22 (2) (2023)
Amanda W Pong, Ivana Tyrlikova, Alexander J Giermek, Pavel Klein
Impact of regulatory safety warnings and restrictions on drug treatment of epilepsy. Expert opinion on drug safety 22 (2) (2023)
Steven G Chrysant
Superior stroke prevention with angiotensin receptor blockers compared with other antihypertensive drugs. Expert opinion on drug safety 22 (2) (2023)
Ahmad Z Al Meslamani
Medication errors during a pandemic: what have we learnt? Expert opinion on drug safety 22 (2) (2023)
Ahmad Z Al Meslamani
Medication errors during a pandemic: what have we learnt? Expert opinion on drug safety 22 (2) (2023)
Hai-Bin Chen, Rong-Sen Meng, Yao-Lin Yang, Tian-Hao Yu
The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. Expert opinion on drug safety 22 (2) (2023)
Liana Michaud, Matthew Seplowe, Juliet Meir, Wilbert S Aronow
Safety and cardiometabolic efficacy of novel antidiabetic drugs. Expert opinion on drug safety 22 (2) (2023)
Amanda W Pong, Ivana Tyrlikova, Alexander J Giermek, Pavel Klein
Impact of regulatory safety warnings and restrictions on drug treatment of epilepsy. Expert opinion on drug safety 22 (2) (2023)
Hai-Bin Chen, Rong-Sen Meng, Yao-Lin Yang, Tian-Hao Yu
The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. Expert opinion on drug safety 22 (2) (2023)
Steven G Chrysant
Superior stroke prevention with angiotensin receptor blockers compared with other antihypertensive drugs. Expert opinion on drug safety 22 (2) (2023)

volume 21, number 12, 2023

Giacomo Casalini, Andrea Giacomelli, Spinello Antinori
Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review. Expert opinion on drug safety 21 (12) (2023)